Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market
Rhea-AI Summary
Sunshine Biopharma (NASDAQ:SBFM) has launched its generic Amoxicillin in Canada and has begun shipping to pharmacies, offering multiple dosages and strengths. The move expands the company's portfolio of essential generic antibiotics and supports access to affordable, high-quality treatment for a wide range of bacterial infections.
According to Sunshine Biopharma, global Amoxicillin sales were about $4.9 billion in 2025 and are projected to grow at a 2.9% CAGR to roughly $6.4 billion by 2031. Canada represents approximately 2% of this global market. The company currently markets 60 generic drugs in Canada, with about 12 more launches planned for 2026.
Positive
- Launch of generic Amoxicillin in Canada with shipments to pharmacies already underway
- Amoxicillin global market estimated at $4.9 billion in 2025, projected to reach about $6.4 billion by 2031
- Portfolio scale: 60 generic prescription drugs on the Canadian market with ~12 additional launches planned in 2026
Negative
- None.
Market reaction after generic Amoxicillin launch: SBFM -13.21%
Following this news, SBFM has declined 13.21%, reflecting a significant negative market reaction. Our momentum scanner has triggered 52 alerts so far, indicating high trading interest and price volatility. The stock is currently trading at $1.22. Trading volume is exceptionally heavy at 40.1x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 04 | Canadian drug approval | Positive | +12.0% | Canadian approval expanded the generic women’s health portfolio |
| Jul 28 | Canadian drug approval | Positive | -6.5% | Health Canada approved generic ondansetron tablets for Canadian distribution |
| Jul 20 | Research publication | Positive | -3.9% | Peer-reviewed research reported PLpro inhibitor activity across coronavirus variants |
| Jun 25 | Canadian regulatory approval | Positive | +4.9% | Canadian approval added generic anastrozole to the company portfolio |
| Jun 01 | Canadian drug approval | Positive | -5.9% | Canadian approval expanded the generic anticoagulant portfolio |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history was mixed: three of five positive or progress-related announcements had negative 24-hour reactions, while two had positive reactions.
Key Terms
cagr financial
penicillin-class antibiotic medical
mrna-lipid nanoparticle technical
plpro protease inhibitor medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Sunshine Biopharma's Amoxicillin now shipping to Canadian pharmacies in multiple dosages and strengths
Launch expands Sunshine Biopharma's growing portfolio of essential prescription medications
Global Amoxicillin market projected to reach approximately
$6.4 billion by 2031
FORT LAUDERDALE, FL / ACCESS Newswire / August 7, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the launch of its generic Amoxicillin formulation in the Canadian market. This strategic expansion reinforces Sunshine Biopharma's commitment to providing affordable, high-quality antibiotics to patients across Canada.
Amoxicillin, a widely prescribed penicillin-class antibiotic, is used to treat a variety of bacterial infections including ear infections, sinus infections, strep throat, pneumonia, bronchitis, urinary tract infections, skin and soft-tissue infections, and dental infections. Sunshine Biopharma's generic version will be available in multiple dosages and strengths, ensuring broad accessibility for prescribers and pharmacists. Sunshine Biopharma started shipping Amoxicillin to pharmacies this week.
Amoxicillin global sales in 2025 were estimated to be
"We are proud to add Amoxicillin to our expanding portfolio of generic antibiotics," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "This launch aligns with our mission to deliver essential medications at competitive prices while maintaining the highest standards of quality and compliance."
About Sunshine BiopharmaInc.
Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire